EUVIMEDEUVIMED entdecken
Crossref

Decitabine Protects Against Autoimmunity‐Mediated Bone Loss and Death in Foxp3‐Deficient Scurfy Mice

Abdul Malik Tyagi iD, Md Fahim Ahmad iD, Musarrat Naaz iD, Marwa Zeyad iD, Gaurav Swarnkar iD, Yousef Abu-Amer iD

Immunology · 04.11.2026

DOI: 10.1111/imm.70220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, online erschienen am 04.11.2026. Verfasst von Abdul Malik Tyagi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA. Die Arbeit nennt 35 Literaturangaben. Gefördert von: NIH HHS, Shriners Hospitals for Children, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Foxp3‐dependent regulatory T cells (Tregs) are essential for immune tolerance and skeletal homeostasis. Loss of Foxp3 function results in severe immune dysregulation, enteropathy and osteopenia, as observed in human IPEX syndrome and the scurfy (SF) mouse model. This study evaluated the therapeutic potential of the DNA methyltransferase inhibitor decitabine (DAC) to mitigate immune pathology and skeletal deterioration in Foxp3‐deficient SF mice. SF mice received DAC treatment for 12 weeks and were monitored for survival, body weight and splenomegaly. Bone microarchitecture was assessed using microcomputed tomography. Serum bone turnover markers, immune cell subsets, inflammatory cytokines, gene expression profiles, haematopoietic progenitors and osteoclastogenesis in T cell–macrophage co‐cultures were analysed to determine DAC's systemic and skeletal effects. DAC treatment significantly prolonged survival, stabilized body weight and reduced splenomegaly in SF mice. Trabecular bone mass was preserved, accompanied by reduced serum CTX levels, indicating suppression of osteoclast‐mediated bone resorption. DAC attenuated systemic inflammation by decreasing pathogenic TCRβ + T cells, Th17 cells, IL‐17A + T cells and autoantibody‐producing B‐cell subsets in spleen and bone marrow. Expression of osteoclastogenic cytokines (TNF‐α, RANKL and IL‐6) and inflammatory genes was normalized. DAC also corrected haematopoietic progenitor abnormalities and reduced osteoclast formation in co‐culture assays. These findings demonstrate that DAC restores immune balance, suppresses excessive osteoclastogenesis, preserves skeletal integrity, and improves survival in Foxp3‐deficient SF mice. The results support DAC's translational potential as a therapeutic strategy for IPEX syndrome and related disorders characterized by Treg dysfunction.

Schlagwörter

Stichwörter der Autor:innen

Foxp3IPEX syndromebone lossdecitabineregulatory T cellsscurfy mice

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Shriners Hospitals for Children, St. Louis, Missouri, USA.

ORCID-Profile: Abdul Malik Tyagi, Md Fahim Ahmad, Musarrat Naaz, Marwa Zeyad, Gaurav Swarnkar, Yousef Abu-Amer

Förderung

  • NIH HHS
  • Shriners Hospitals for Children
  • National Institutes of Health

Zitieren

APA

Tyagi, A. M., Ahmad, M. F., Naaz, M., Zeyad, M., Swarnkar, G., & Abu-Amer, Y. (2026). Decitabine Protects Against Autoimmunity‐Mediated Bone Loss and Death in Foxp3‐Deficient Scurfy Mice. Immunology. https://doi.org/10.1111/imm.70220

Vancouver

Tyagi AM, Ahmad MF, Naaz M, Zeyad M, Swarnkar G, Abu-Amer Y. Decitabine Protects Against Autoimmunity‐Mediated Bone Loss and Death in Foxp3‐Deficient Scurfy Mice. Immunology. 2026. doi:10.1111/imm.70220

BibTeX
@article{Tyagi2026,
  author = {Tyagi, Abdul Malik and Ahmad, Md Fahim and Naaz, Musarrat and Zeyad, Marwa and Swarnkar, Gaurav and Abu-Amer, Yousef},
  title = {Decitabine Protects Against Autoimmunity‐Mediated Bone Loss and Death in Foxp3‐Deficient Scurfy Mice},
  journal = {Immunology},
  year = {2026},
  doi = {10.1111/imm.70220}
}
Kostenlos starten →